Please assess the completion status of the following clinical trial:

Trial Title: Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed resectable adenocarcinoma of the breast~  * pT1, pT2, pT3, or minimal dermal involvement on pathology only~ * pN0, pN1, pN2, or M0~    * Negative nodal status~      * At least 8 nodes are negative~   * Unknown nodal status~      * Less than 8 nodes examined and no pathological finding~   * Positive nodal status~      * Any positive finding independent of the number of nodes examined~ * Negative sentinel node or no prior nodal dissection allowed if all other criteria met~* Must have had total mastectomy, lumpectomy, or quadrantectomy~  * Should have prior chest wall radiotherapy after segmental mastectomy or histopathologic T4 dermal involvement~* Stage I, II, or IIIa allowed if the tumor is completely removed macroscopically and margins of the resected tumor are microscopically free of tumor~* Must undergo chest wall radiotherapy or second resection if microscopic disease at the mastectomy margins~* No bilateral disease except in situ disease, either ductal or lobular of the contralateral breast~* Postmenopausal~  * Regardless of prior hormonal replacement therapy (HRT) or hysterectomy:~    * Bilateral oophorectomy and any age~   * Radiologic castration and amenorrheic for at least 3 months and any age~   * Not postmenopausal at the start of adjuvant chemotherapy AND and completed at least 6 courses of prior cyclophosphamide, methotrexate, and fluorouracil (CMF) or at least 4 courses of prior anthracycline-cyclophosphamide continuation therapy and at least age 45 with follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) postmenopausal levels~ * No prior HRT:~    * Prior hysterectomy and less than age 55 with FSH/LH/E2 postmenopausal levels~   * Prior hysterectomy and at least age 55~ * No prior HRT or hysterectomy:~    * Amenorrhea more than 1 year and less than age 50~   * Amenorrhea more than 6 months and at least age 50~ * Prior HRT regardless of hysterectomy:~    * At least 1 month since prior HRT and less than age 55 with FSH/LH/E2 postmenopausal levels~   * At least 1 month since prior HRT and at least age 55~ * FSH/LH/E2 postmenopausal levels and uncategorized~* No distant metastases, including bone scans showing hot spots unconfirmed as benign disease or skeletal pain of unknown cause~* At least 10% hormone receptor-positive tumor cells~* Hormone receptor status:~  * Estrogen receptor positive AND/OR~ * Progesterone receptor positive~PATIENT CHARACTERISTICS:~Age:~* 30 and over~Sex:~* Female~Menopausal status:~* Postmenopausal~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* WBC greater than 3,000/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin greater than 10 g/dL~Hepatic:~* Bilirubin less than 3.0 mg/dL~* SGOT or SGPT less than 1.5 times upper limit of normal~* No hepatic disease that would preclude study~Renal:~* Creatinine less than 1.8 mg/dL~* No renal disease that would preclude study~Cardiovascular:~* No cardiovascular disease that would preclude study~* Prior deep vein thrombosis allowed if medically stable~Pulmonary:~* No lung embolism~Other:~* No other prior or concurrent malignancy within the past 5 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix~* No prior noncompliance to medical regimens~* No other nonmalignant systemic diseases that would preclude follow-up~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Prior immunotherapy or biological response modifiers (e.g., interferon) allowed~Chemotherapy:~* See Disease Characteristics~* Prior adjuvant or neoadjuvant chemotherapy allowed~* Concurrent adjuvant chemotherapy allowed~Endocrine therapy:~* See Disease Characteristics~* Prior neoadjuvant hormonal therapy allowed (e.g., antiestrogens, progestins, or aromatase inhibitors) if no more than 4 months duration and no disease progression~* Prior corticosteroids allowed~* At least 4 weeks since prior HRT~* Prior adjuvant antiestrogen therapy allowed if less than 1 month duration and immediately after surgery, radiotherapy, and/or chemotherapy~* Prior antiestrogens for chemoprevention allowed if at least 18 months between completion of chemoprevention and diagnosis~* No other concurrent antiestrogens or aromatase inhibitors~* No concurrent raloxifene~* No concurrent systemic HRT with or without progestins of more than 3 months duration~Radiotherapy:~* See Disease Characteristics~* Concurrent radiotherapy allowed~Surgery:~* See Disease Characteristics~Other:~* At least 30 days since prior systemic investigational drugs~* At least 7 days since prior topical investigational drugs~* Concurrent bisphosphonates allowed

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Tamoxifen (Type: EXPERIMENTAL): Tamoxifen for 5 years after randomization.
- Letrozole (Type: EXPERIMENTAL): Letrozole for 5 years after randomization.
- Tamoxifen, then letrozole (Type: EXPERIMENTAL): Tamoxifen for 2 years after randomization, then letrozole for the next 3 years.
- Letrozole, then tamoxifen (Type: EXPERIMENTAL): Letrozole for 2 years after randomization, then tamoxifen for the next 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete